tirzepatide and glaucoma Use of the dual GIP/GLP-1 drug (Mounjaro, Zepbound) was associated with a significantly reduced risk of compared with GLP-1 drugs among patients with type 2 diabetes, a large retrospective cohort Glaucomatous Optic Neuropathy & Latest

In late 2023, lawyers filed a motion to consolidate similar Ozempic lawsuits into one mass legal action

In general, lab work would be required yearly for ongoing therapy or regular intermittent therapy throughout the year

& Klitgaard, H

Refining Indications: Instead of a general "healing compound," future research might narrow down specific indications where BPC-157's mechanisms are most impactful and where it can demonstrate superior efficacy or safety compared to existing treatments

Cost: Compounded variations often come at a lower cost, but patients need to weigh this against the potential risks of unregulated formulations

That is the wrong place to look